Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DARANIDE vs ACETAZOLAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Edema due to congestive heart failure,Drug-induced edema,Glaucoma (adjunctive therapy)
Edema due to congestive heart failure (adjunctive therapy),Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Chronic simple (open-angle) glaucoma,Secondary glaucoma,Preoperative lowering of intraocular pressure in acute angle-closure glaucoma,Altitude sickness (prevention and treatment),Off-label: Idiopathic intracranial hypertension, metabolic alkalosis, sleep apnea, bipolar disorder, cystinuria, hypokalemic periodic paralysis
50 mg orally once or twice daily; maximum 100 mg/day.
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
Terminal elimination half-life: 2.5-3.5 hours (prolonged in renal impairment). Clinical context: Short half-life necessitates multiple daily dosing for sustained diuretic effect.
Terminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
Not extensively metabolized; excreted unchanged in urine.
Primarily excreted unchanged in urine (70-100%). Minor metabolism via hydrolysis of acetyl group (possibly by plasma esterases) to acetazolamide, and glucuronide conjugation.
Renal: unchanged drug (approximately 50% of absorbed dose) and metabolites. Biliary/fecal: minimal.
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
~90% bound, primarily to albumin.
~70–90% bound primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
0.2-0.3 L/kg. Clinical meaning: Confined primarily to extracellular fluid; low Vd indicates minimal tissue distribution.
0.2–0.3 L/kg; concentrates in tissues with high carbonic anhydrase content (RBCs, kidneys, eyes).
Oral: 75-85% (tablet).
Oral: ~100% (well absorbed); IV: 100%.
GFR 10-50 m L/min: 50 mg every 12-24 hours; GFR <10 m L/min: 50 mg every 24-48 hours; not effective if GFR <10 m L/min.
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: avoid use (ineffective).
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: use not recommended.
Child-Pugh class A: no adjustment; Child-Pugh class B-C: caution, reduce dose by 50% and monitor for encephalopathy.
Not established; use not recommended in children.
Children: 5-10 mg/kg/dose orally or IV every 8-12 hours; maximum 500 mg/dose.
Start at 25 mg once daily; monitor renal function and electrolyte balance due to increased risk of adverse effects.
Initiate at lowest effective dose (250 mg daily) due to increased risk of electrolyte disturbances and renal impairment.
None.
WARNING: Metabolically induced acidosis. Use with caution in patients with hepatic cirrhosis to avoid precipitation of hepatic encephalopathy. Not recommended for long-term use in patients with chronic noncongestive angle-closure glaucoma due to risk of increased intraocular pressure with lens displacement.
May cause drowsiness, confusion, or paresthesias,Monitor electrolytes and renal function,Can cause metabolic acidosis,Use caution in patients with hepatic impairment or cirrhosis
Sulfonamide hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) - discontinue at first sign of rash,Metabolic acidosis - monitor electrolytes, use with caution in patients with respiratory acidosis or those at risk,Hepatic impairment - contraindicated in cirrhosis; may precipitate hepatic encephalopathy,Renal impairment (Cr Cl <10 m L/min) - ineffective and may cause metabolic acidosis,Hematologic reactions (agranulocytosis, aplastic anemia) - monitor CBC,Hypercalciuria and renal stone formation - ensure adequate hydration,Drowsiness, confusion, fatigue - impaired ability to drive/operate machinery,Use in pregnancy - potential risk; cross-sensitivity with sulfonamides
Hypersensitivity to dichlorphenamide or other sulfonamides,Severe renal or hepatic dysfunction,Hypokalemia,Hyponatremia,Metabolic acidosis,Adrenal insufficiency
Hypersensitivity to acetazolamide or any sulfonamide derivative,Severe hepatic cirrhosis or hepatic impairment,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Adrenocortical insufficiency (Addison's disease),Long-term use in chronic noncongestive angle-closure glaucoma,Metabolic acidosis
No specific food interactions reported. However, maintain adequate hydration to reduce risk of kidney stones. Avoid excessive salt intake if edema is present. Grapefruit juice is not known to interact.
Avoid high doses of vitamin C or cranberry juice as they may acidify urine and decrease drug effectiveness. Maintain adequate hydration; no specific food restrictions.
Pregnancy Category C. First trimester: Possible association with congenital malformations (limited human data; animal studies show fetal toxicity). Second/third trimester: Risk of electrolyte disturbances and acidosis in neonate; avoid use unless benefit outweighs risk.
First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause fetal metabolic acidosis, electrolyte disturbances, and growth retardation.
Contraindicated in breastfeeding. Excreted in breast milk; M/P ratio not established. Potential for serious adverse effects in infant (metabolic acidosis, electrolyte imbalance).
Excreted into breast milk (M/P ratio approximately 0.25). Not recommended due to risk of sulfonamide-related adverse effects (e.g., kernicterus in jaundiced infants, hemolytic anemia in G6PD deficiency).
No standard dose adjustments; increased renal clearance in pregnancy may lower drug levels, but empirical dose changes are not recommended due to risk of metabolic acidosis. Use lowest effective dose if unavoidable.
No standard dose adjustment recommended; pharmacokinetics altered (increased Vd, decreased Cmax) but clinical significance uncertain. Monitor for metabolic acidosis and adjust if necessary.
DARANIDE (dichlorphenamide) is a carbonic anhydrase inhibitor used for chronic open-angle glaucoma and secondary glaucoma. Monitor for metabolic acidosis, especially in patients with renal impairment. Can cause hypokalemia; check serum potassium periodically. Avoid concurrent use with high-dose salicylates due to risk of metabolic acidosis and salicylate toxicity. May cause drowsiness or confusion; caution in elderly. Not a first-line agent; reserved for patients intolerant or unresponsive to other therapies.
Acetazolamide is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and as a diuretic. Monitor serum electrolytes (especially potassium and bicarbonate) due to metabolic acidosis risk. Avoid in severe hepatic or renal impairment. Can cause paresthesias, especially in hands and feet. Use with caution in patients with sulfonamide allergy as cross-reactivity is possible but rare.
Take exactly as prescribed, usually 3-4 times daily with food to reduce GI upset.,May cause tingling or numbness in fingers, toes, or mouth; this is common and usually harmless.,Drink plenty of fluids to prevent kidney stones; report painful urination or blood in urine.,Avoid aspirin or high-dose salicylates; check with doctor before taking any OTC pain relievers.,Regular eye exams and blood tests (potassium, bicarbonate) are necessary.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Tell your doctor if you have kidney disease, liver disease, or electrolyte imbalance.,Notify your doctor if you experience weakness, weight loss, confusion, or rapid breathing.
Take exactly as prescribed; do not stop suddenly.,May cause tingling or numbness in fingers, toes, or mouth; this is usually temporary.,Drink plenty of fluids unless otherwise directed; avoid excessive alcohol.,Report unusual fatigue, muscle cramps, or rapid breathing to your doctor.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,If used for altitude sickness, start 1-2 days before ascent and continue during climb.
No interactions on record
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DARANIDE vs ACETAZOLAMIDE, answered by our medical review team.
DARANIDE is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor. Inhibits carbonic anhydrase in the proximal renal tubule, reducing bicarbonate reabsorption and causing alkaline diuresis.. ACETAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DARANIDE and ACETAZOLAMIDE depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DARANIDE is: 50 mg orally once or twice daily; maximum 100 mg/day.. The standard adult dose of ACETAZOLAMIDE is: 250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DARANIDE and ACETAZOLAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DARANIDE is classified as Category C. Pregnancy Category C. First trimester: Possible association with congenital malformations (limited human data; animal studies show fetal toxicity). Second/third trimester: Risk of . ACETAZOLAMIDE is classified as Category C. First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.